Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2016

01.01.2016 | Original Article

Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging

verfasst von: Go Akamatsu, Yasuhiko Ikari, Tomoyuki Nishio, Hiroyuki Nishida, Akihito Ohnishi, Kazuki Aita, Masahiro Sasaki, Masayuki Sasaki, Michio Senda

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The purpose of this study was to optimize image reconstruction conditions for brain 18F-FDG, 11C-PiB, 18F-florbetapir and 18F-flutemetamol PET imaging with Discovery-690 PET/CT for diagnosis and research on Alzheimer’s disease (AD) based on the standard imaging protocols and phantom test procedures and criteria published by the Japanese society of nuclear medicine (JSNM).

Methods

A Hoffman 3D brain phantom and a cylindrical pool phantom were scanned according to the JSNM procedure, and the reconstruction conditions (iteration, subset, post-filter) were optimized so that the images satisfy the JSNM criteria regarding spatial resolution (FWHM ≤8 mm) and gray/white matter contrast (%contrast ≥55 %) on the Hoffman phantom and uniformity (SD of small ROIs ≤0.0249) and image noise (coefficient of variation ≤15 %) on the pool phantom. Human images were acquired with 18F-FDG (15-min scan starting at 30 min post-injection [p.i.] of 185 MBq), 11C-PiB (20-min scan starting at 50 min p.i. of 555 MBq), 18F-florbetapir (10-min scan starting at 50 min p.i. of 370 MBq) and 18F-flutemetamol (30-min scan starting at 90 min p.i. of 185 MBq) on 1 or 2 subjects for each tracer and reconstructed with thus determined conditions to evaluate the image quality visually. The effect of reconstruction parameters on the standardized uptake value ratio (SUVR) was also evaluated on 5 amyloid-positive and 5 amyloid-negative PiB images.

Results

A sufficient image quality was obtained at an iterative update (product of iteration and subset) of 64 for 18F-FDG. The same reconstruction parameters with an additional Gaussian filter of 5 mm FWHM was optimal for 11C-PiB, 18F-florbetapir and 18F-flutemetamol to achieve the phantom criteria. Those optimal reconstruction conditions were confirmed with human images. The SUVR value was stable over a wide range of iterative updates around the optimal parameters both for positive and negative amyloid images.

Conclusions

Optimal image reconstruction conditions were determined for brain 18F-FDG and amyloid PET imaging with Discovery-690 PET/CT for diagnosis and research on AD based on the JSNM phantom criteria. This supports feasibility of the phantom criteria for standardization and harmonization of brain 18F-FDG and amyloid PET for multicenter studies.
Literatur
1.
Zurück zum Zitat Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.CrossRefPubMed Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.CrossRefPubMed
2.
Zurück zum Zitat Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.CrossRefPubMed Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.CrossRefPubMed
3.
Zurück zum Zitat Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40.PubMed Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40.PubMed
4.
Zurück zum Zitat Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.PubMedCentralCrossRefPubMed Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed
6.
Zurück zum Zitat Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.CrossRefPubMed Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.CrossRefPubMed
7.
Zurück zum Zitat Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878–86.PubMedCentralCrossRefPubMed Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878–86.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6:221–9.PubMedCentralCrossRefPubMed Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6:221–9.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Iwatsubo T. Japanese Alzheimer’s Disease Neuroimaging Initiative: present status and future. Alzheimers Dement. 2010;6:297–9.CrossRefPubMed Iwatsubo T. Japanese Alzheimer’s Disease Neuroimaging Initiative: present status and future. Alzheimers Dement. 2010;6:297–9.CrossRefPubMed
11.
Zurück zum Zitat Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.CrossRefPubMed Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.CrossRefPubMed
12.
Zurück zum Zitat Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedCentralCrossRefPubMed Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570–6.CrossRefPubMed van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570–6.CrossRefPubMed
14.
Zurück zum Zitat Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Någren K, et al. Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI. Eur J Nucl Med Mol Imaging. 2014;41:283–9.CrossRefPubMed Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Någren K, et al. Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI. Eur J Nucl Med Mol Imaging. 2014;41:283–9.CrossRefPubMed
15.
Zurück zum Zitat Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J, et al. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol. 2013;20:1043–52.CrossRefPubMed Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J, et al. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol. 2013;20:1043–52.CrossRefPubMed
16.
Zurück zum Zitat Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535–44.CrossRefPubMed Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535–44.CrossRefPubMed
17.
Zurück zum Zitat Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7.PubMedCentralCrossRefPubMed Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET/CT Discovery-690. Med Phys. 2011;38:5394–411.CrossRefPubMed Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET/CT Discovery-690. Med Phys. 2011;38:5394–411.CrossRefPubMed
23.
Zurück zum Zitat Conti M. Focus on time-of-flight PET: the benefits of improved time resolution. Eur J Nucl Med Mol Imaging. 2011;38:1147–57.CrossRefPubMed Conti M. Focus on time-of-flight PET: the benefits of improved time resolution. Eur J Nucl Med Mol Imaging. 2011;38:1147–57.CrossRefPubMed
24.
Zurück zum Zitat Hoffman EJ, Cutler PD, Guerrero TM, Digby WM, Mazziotta JC. Assessment of accuracy of PET utilizing a 3-D phantom to simulate the activity distribution of [18F]fluorodeoxyglucose uptake in the human brain. J Cereb Blood Flow Metab. 1991;11:A17–25.CrossRefPubMed Hoffman EJ, Cutler PD, Guerrero TM, Digby WM, Mazziotta JC. Assessment of accuracy of PET utilizing a 3-D phantom to simulate the activity distribution of [18F]fluorodeoxyglucose uptake in the human brain. J Cereb Blood Flow Metab. 1991;11:A17–25.CrossRefPubMed
25.
Zurück zum Zitat Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358–66.PubMed Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358–66.PubMed
26.
Zurück zum Zitat Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol. 2010;37:497–508.CrossRefPubMed Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol. 2010;37:497–508.CrossRefPubMed
27.
Zurück zum Zitat Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.CrossRefPubMed Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.CrossRefPubMed
31.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMed
32.
Zurück zum Zitat Imabayashi E, Matsuda H, Tabira T, Arima K, Araki N, Ishii K, et al. Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer’s disease. Brain Behav. 2013;3:487–93.PubMedCentralCrossRefPubMed Imabayashi E, Matsuda H, Tabira T, Arima K, Araki N, Ishii K, et al. Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer’s disease. Brain Behav. 2013;3:487–93.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz HJ, et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40:238–44.CrossRefPubMed Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz HJ, et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40:238–44.CrossRefPubMed
35.
Zurück zum Zitat Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18.CrossRefPubMed Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18.CrossRefPubMed
36.
Zurück zum Zitat Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14.PubMedCentralCrossRefPubMed Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14.PubMedCentralCrossRefPubMed
Metadaten
Titel
Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging
verfasst von
Go Akamatsu
Yasuhiko Ikari
Tomoyuki Nishio
Hiroyuki Nishida
Akihito Ohnishi
Kazuki Aita
Masahiro Sasaki
Masayuki Sasaki
Michio Senda
Publikationsdatum
01.01.2016
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-1024-0

Weitere Artikel der Ausgabe 1/2016

Annals of Nuclear Medicine 1/2016 Zur Ausgabe